Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-[(3R)-3-{[2-(4-fluorophenyl)-2-oxoethyl]amino}butyl]benzamide
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
01
Overview
4-[(3R)-3-{[2-(4-fluorophenyl)-2-oxoethyl]amino}butyl]benzamide is a synthetic small molecule belonging to the class of alkyl phenylketones. It acts as a potent inhibitor of dipeptidyl peptidase 4 (DPP4), an enzyme involved in glucose metabolism and immune regulation. The compound has demonstrated nanomolar inhibitory activity against human DPP4 in biochemical assays, with reported IC50 values around 84 nM. It was developed and studied by Eli Lilly as part of research into DPP4 inhibitors, which are relevant for the treatment of type 2 diabetes mellitus due to their role in prolonging incretin hormone activity and enhancing insulin secretion[1][8]. There is no evidence that this compound has reached clinical development or been marketed.
- Other names
- 4-((3R)-3-((2-(4-fluorophenyl)-2-oxoethyl)amino)butyl)benzamideSCHEMBL23752242SCHEMBL-23752242SCHEMBL 23752242
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on 4-[(3R)-3-{[2-(4-fluorophenyl)-2-oxoethyl]amino}butyl]benzamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-[(3R)-3-{[2-(4-fluorophenyl)-2-oxoethyl]amino}butyl]benzamide.